The first annual Obliteride – a fundraising bike ride to sport lifesaving cancer research at the Fred Hutchinson Center – will soon spin through Auburn.
The Aug. 9-11 event offers various distances and terrains for riders of all levels, and features an entire weekend of celebration and concerts.
Routes for the 25-, 50-, 100- and 180-mile rides have just been released at obliteride.org/ride.
“Obliteride is a community-wide event that everyone can participate in by riding, volunteering or cheering on participants as they roll though your community,” said Amy Lavin, Obliteride’s executive director. “We would love to see people get involved by volunteering or lining the streets with signs honoring loved ones or friends who have battled cancer or are in the fight today. Simply come to the end of your driveway and cheer on the riders. We’d love to see everyone out there.”
All proceeds directly benefit lifesaving cancer research.
All routes will start in northeast Seattle at Magnuson Park on Aug. 10. Participants in the 25-mile, 50-mile, and 100-mile rides will return to Magnuson Park on Saturday to enjoy a full finish line celebration.
Participants in the 180-mile (two-day) ride will continue to the University of Puget Sound in Tacoma, spend the night there and return to Magnuson Park on Aug. 11. Detailed route maps will be available early spring.
Sign up to ride, volunteer or fundraise at obliteride.org.
Route maps are now available at obliteride.org/ride and short highlight videos of each route are at obliteride.org.
About Obliteride
Driven by the goal to end cancer, Obliteride is a new, community-wide effort to accelerate lifesaving cancer research at Fred Hutchinson Cancer Research Center. It has created a movement of people committed to obliterating cancer and saving lives faster. It culminates in a fundraising bike ride Aug. 9-11 that will be quintessentially Northwest. Thanks to early anchor sponsors, University Village and The Sloan Foundation, and other inaugural sponsors, 100 percent of every dollar raised goes directly to breakthrough cancer research at Fred Hutch.
